Table 1.
Patient characteristics.
| Characteristic | All Patients | LEN Combined with TIT | LEN Monotherapy | p |
|---|---|---|---|---|
| n | 115 | 30 | 85 | |
| Age (years old) | 71 (38–89) | 63 (38–78) | 73 (44–89) | <0.001 |
| Sex (female/male) | 23/92 | 5/25 | 18/67 | 0.590 |
| PS (0/1/2) | 105/8/1 | 28/2/0 | 77/7/1 | 0.475 |
| Etiology (HBV/HCV/Others) | 27/46/42 | 9/8/13 | 18/38/29 | 0.205 |
| ALBI score (Median (range)) |
−2.50 (−3.34–−1.49) |
−2.66 (−3.34–−1.91) |
−2.47 (−3.33–−1.49) |
0.001 |
| m-ALBI grade (1/2a/2b) | 47/34/34 | 18/6/6 | 29/28/28 | 0.047 |
| Tumor size (mm) | 40 (11–190) | 40 (11–190) | 40 (10–135) | 0.396 |
| Number tumors <5/≥5 |
31/84 | 8/22 | 23/62 | 0.966 |
| Macrovascular invasion (No/Yes) |
87/28 | 18/12 | 69/16 | 0.024 |
| Extrahepatic spread (No/Yes) |
27/88 | 10/20 | 17/68 | 0.138 |
| Initial dose of LEN | 0.454 | |||
| 12 mg | 31 | 10 | 21 | |
| 8 mg | 71 | 15 | 56 | |
| 8 mg weekend methods | 3 | 2 | 1 | |
| 4 mg | 8 | 2 | 6 | |
| 4 mg weekend methods | 2 | 1 | 1 | |
| Combination therapy | n.s. | |||
| TACE | 12 | 12 | ||
| HAIC | 18 | 18 | ||
| AFP (ng/mL) | 92.7 (1.0–146,260) |
78.9 (1.7–56,225) |
133.0 (1.0–146,260) |
0.605 |
| Treatment line (1st/2nd/3rd) |
77/27/11 | 21/6/3 | 56/21/8 | 0.869 |
Data are expressed as a median (range) or number. Abbreviations: LEN, lenvatinib; TIT; Transcatheter intra-arterial therapies; PS, Performance Status; HBV, hepatitis B virus; HCV, hepatitis C virus; ALBI score, albumin-bilirubin score; TACE, transcatheter arterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; AFP, α-fetoprotein.